×
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
NASDAQ:BIVI

BioVie News Headlines

$1.44
-0.10 (-6.49%)
(As of 06/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.40
$1.54
50-Day Range
$1.54
$4.33
52-Week Range
$1.40
$17.20
Volume
81,606 shs
Average Volume
50,060 shs
Market Capitalization
$35.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50
Get BioVie News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter.

BIVI Media Mentions By Week

BIVI Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BIVI
News Sentiment

1.04

0.40

Average
Medical
News Sentiment

BIVI News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BIVI Articles
This Week

3

0

BIVI Articles
Average Week



BIVI Stock News Headlines Today

SourceHeadline
marketwatch.com logoBioVie Shares Rise 18% After Patent Issued for Terlipressin Monotherapy
marketwatch.com - June 23 at 3:47 PM
seekingalpha.com logoMicro-cap BioVie rises after getting back patent protection for its ascites treatment
seekingalpha.com - June 23 at 9:49 AM
finance.yahoo.com logoBioVie Announces Patent Issuance Covering Ascites Treatment with BIV201
finance.yahoo.com - June 23 at 9:49 AM
MarketBeat logoBioVie Inc. (NASDAQ:BIVI) Short Interest Down 35.7% in May
americanbankingnews.com - June 14 at 4:44 AM
seekingalpha.com logoBioVie: Four Potential Catalysts Around The Corner
seekingalpha.com - June 9 at 9:35 AM
MarketBeat logoBioVie (NASDAQ:BIVI) Rating Increased to Buy at Zacks Investment Research
americanbankingnews.com - June 5 at 3:54 AM
MarketBeat logoBioVie (NASDAQ:BIVI) Stock Rating Lowered by Zacks Investment Research
americanbankingnews.com - June 4 at 2:54 AM
finance.yahoo.com logoBioVie to Participate at the B. Riley Securities’ Neuro & Ophthalmology Conference
finance.yahoo.com - April 25 at 8:58 AM
benzinga.com logoOppenheimer Initiates Coverage On BioVie with Outperform Rating, Announces Price Target of $9
benzinga.com - March 15 at 3:11 PM
finance.yahoo.com logoBioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®
finance.yahoo.com - March 10 at 11:08 AM
finance.yahoo.com logoBioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference
finance.yahoo.com - March 9 at 8:20 PM
seekingalpha.com logoBioVie begins treatment in phase 2 trial of NE3107 for Parkinson's disease
seekingalpha.com - January 20 at 10:49 AM
finance.yahoo.com logoBioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease
finance.yahoo.com - January 20 at 10:49 AM
finance.yahoo.com logoBioVie Announces Partnership with the American Liver Foundation
finance.yahoo.com - December 9 at 8:15 AM
finance.yahoo.com logoBioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.
finance.yahoo.com - December 1 at 8:16 AM
finance.yahoo.com logoBioVie Hosting Key Opinion Leader Webinar on Complications of Advanced Liver Cirrhosis and BIV201 Phase 2b Clinical Trial Update
finance.yahoo.com - November 4 at 2:59 PM
finance.yahoo.com logoBioVie Announces the Appointment of a New Chief Medical Officer
finance.yahoo.com - November 1 at 9:47 AM
benzinga.com logoBioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107's Pro-motoric Activity in Parkinson's Disease
benzinga.com - October 27 at 11:06 PM
marketwatch.com logoBioVie Gets FDA Approval to Start Trial for Parkinson's Treatment
marketwatch.com - October 26 at 3:45 PM
msn.com logoBRIEF-BioVie Inc Announces FDA Authorization To Initiate Phase 2 Trials Assessing NE3107’s Pro-Motoric Activity In Parkinson’S Disease
msn.com - October 26 at 10:45 AM
finance.yahoo.com logoBioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107’s Pro-motoric Activity in Parkinson’s Disease
finance.yahoo.com - October 26 at 10:45 AM
finance.yahoo.com logoBioVie Hosting Key Opinion Leader Webinar on Neuroinflammation and Insulin Resistance and New Treatment Approaches for Alzheimer’s Disease
finance.yahoo.com - October 13 at 8:39 AM
finance.yahoo.com logoBioVie to Present at Cantor Virtual Global Healthcare Conference
finance.yahoo.com - September 22 at 12:17 PM
finance.yahoo.com logoBioVie to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit
finance.yahoo.com - September 15 at 8:15 PM
finance.yahoo.com logoBioVie Inc. Announces Closing of Public Offering of Common Stock
finance.yahoo.com - August 11 at 2:53 PM
nasdaq.com logoBioVie Prices Public Offering Of 2.50 Mln Shares At $8.00/shr
nasdaq.com - August 9 at 6:18 AM
finance.yahoo.com logoBioVie Inc. Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - August 8 at 10:30 PM
finance.yahoo.com logoBioVie Inc. Announces Proposed Public Offering of Common Stock
finance.yahoo.com - August 6 at 6:22 PM
finance.yahoo.com logoBioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer’s Disease
finance.yahoo.com - August 5 at 9:37 AM
finance.yahoo.com logoBioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
finance.yahoo.com - July 27 at 8:07 AM
finance.yahoo.com logoBioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
finance.yahoo.com - July 22 at 9:59 AM
finance.yahoo.com logoBasis for BioVie’s Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer’s Disease Published in Neurodegenerative Disease Management
finance.yahoo.com - July 16 at 12:40 PM
finance.yahoo.com logoDevelopment of BioVie’s NE3107 Asset Featured by the American Diabetes Association
finance.yahoo.com - June 29 at 10:35 AM
finance.yahoo.com logoBioVie Added to Russell Microcap® Index
finance.yahoo.com - June 28 at 12:33 PM
msn.com logoBRIEF-BioVie Gets FDA Guidance For Phase 3 Clinical Trial Of BIV201 In HRS-AKI
msn.com - June 25 at 9:40 AM
finance.yahoo.com logoBioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites
finance.yahoo.com - June 24 at 1:04 PM
finance.yahoo.com logoBioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
finance.yahoo.com - June 17 at 8:52 PM
barrons.com logoBioVie Inc.
barrons.com - June 11 at 11:27 PM
finance.yahoo.com logoBioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix
finance.yahoo.com - June 11 at 8:24 AM
finance.yahoo.com logoMoving Average Crossover Alert: BioVie (BIVI)
finance.yahoo.com - May 12 at 8:49 AM
finance.yahoo.com logoBioVie Hosting Research & Development Day
finance.yahoo.com - May 12 at 8:49 AM
finance.yahoo.com logoBioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix
finance.yahoo.com - May 10 at 9:06 AM
finance.yahoo.com logoBioVie to Present at 2021 B. Riley Securities’ Neuroscience Conference
finance.yahoo.com - April 28 at 9:36 AM
finance.yahoo.com logoBioVie to Present at 31st Annual Oppenheimer Healthcare Conference
finance.yahoo.com - March 11 at 7:47 AM
finance.yahoo.com logoBioVie Commences Patient Screening in Phase 2 Clinical Trial
finance.yahoo.com - March 9 at 8:10 AM
finance.yahoo.com logoBioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report®
finance.yahoo.com - February 19 at 7:42 AM
finance.yahoo.com logoNeurMedix Obtains FDA Authorization for Pivotal Phase 3 Alzheimer’s Trial
finance.yahoo.com - February 2 at 10:06 AM
msn.com logoTop Analyst Upgrades and Downgrades: Airbnb, Discovery, DoorDash, Hewlett Packard Enterprise, Intel, Snap, Spotify and More
msn.com - January 15 at 2:26 PM
bloomberg.com logoBioVie Inc
bloomberg.com - December 25 at 10:27 PM
finance.yahoo.com logoBioVie Interview to Air on Bloomberg International on the RedChip Money Report
finance.yahoo.com - October 30 at 8:27 AM
Get BioVie News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:BIVI) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.